(NASDAQ: RNA) Avidity Biosciences's forecast annual revenue growth rate of 178.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Avidity Biosciences's revenue in 2024 is $9,560,000.On average, 1 Wall Street analysts forecast RNA's revenue for 2024 to be $2,261,641,449, with the lowest RNA revenue forecast at $2,261,641,449, and the highest RNA revenue forecast at $2,261,641,449. On average, 1 Wall Street analysts forecast RNA's revenue for 2025 to be $2,261,641,449, with the lowest RNA revenue forecast at $2,261,641,449, and the highest RNA revenue forecast at $2,261,641,449.
In 2026, RNA is forecast to generate $19,294,504,050 in revenue, with the lowest revenue forecast at $19,294,504,050 and the highest revenue forecast at $19,294,504,050.